Abstract:
본 발명은 당뇨병 또는 비만의 예방 또는 치료용 약학 및 식품 조성물에 관한 것으로, 보다 구체적으로는, 남극 지의류인 스테레오카울론 알피넘 ( Stereocaulon alpinum ) 추출물에서 분리한 화합물로부터 합성한 신규 화합물을 유효성분으로 함유하는 당뇨병 또는 비만의 예방 또는 치료용 약학 조성물과 기능성 식품에 관한 것이다. 본 발명에 따른 신규 화합물은 PTP-1b (protein tyrosine phosphatase-1b) 저해활성이 매우 뛰어나며, 단백질타이로신탈인산화효소족 중 PTP-1b에만 선택적으로 작용하고, 실질적인 PTP-1b 저해제로 당뇨치료에 이용가능한바, 당뇨병 및 비만의 예방 또는 치료에 효과적이다.
Abstract:
단백질 타이로신 탈인산화 효소 1B의 활성 억제능을 가지는 남극 지의류 스테레오카울론 알피넘(Stereocaulon alpinum) 추출물 및 이로부터 분리된 우스닉산 유도체가 개시된다. 본 발명에 따른 스테레오카울론 알피넘(Stereocaulon alpinum) 추출물 및 이로부터 분리된 우스닉산 유도체는 당뇨병의 주요 증상인 고혈당에 대한 혈당강하 효과를 갖는다.
스테레오카울론 알피넘(Stereocaulon alpinum), 단백질 타이로신 탈인산화효소 1B(PTP1B)
Abstract:
A Hahella chejuensis mutant strain is provided to stably produce prodigiosin with high yield. A Hahella chejuensis mutant strain M3349(KCTC 11276BP) has high productivity of prodigiosin. A method for isolating the Hahella chejuensis mutant strain M3349(KCTC 11276BP) comprises: a step of treating Hahella chejuensis KCTC 2396 with antibiotics or ethyl methane sulfonate (EMS) to induce mutation; a step of separating a colony in which prodigiosin pigmentation is formed; and a step of culturing the colony in the medium containing antibiotics or carbon source to select a colony having high productivity of prodigiosin.
acrtica ) KOPRI 21653 및 상기 균주 유래 엑소폴리사카라이드(exopolysaccharide)에 관한 것으로, 더욱 자세하게는 슈도알터로모나스 알티카( Pseudoaltermonas
acrtica ) KOPRI 21653 및 상기 균주 유래 항동결능을 가지는 신규 엑소폴리사카라이드, 그 제조 방법 및 이를 함유하는 항동결용 조성물에 관한 것이다. 본 발명에 따른 신규의 엑소폴리사카라이드 및 이를 함유하는 항동결 조성물은 조직의 손상을 최소화하면서 세포 및 조직을 포함하는 생물학적 시료를 냉장, 냉동 및 유리화 상태로 보호 또는 보존하는데 매우 유용하다. 세포외다당체, 엑소폴리사카라이드, 항동결
Abstract:
An algicidal agent containing prodigiosin and a prodigiosin biosynthetic gene cluster are provided to kill reddish brown tide-causing bacteria including Cochlodinium polykrikoides, Gyrodinium impudicum and Heterosigma akashiwo. The prodigiosin biosynthetic gene cluster comprises the nucleotide sequence of SEQ ID NO:1. A method for producing the prodigiosin comprises the steps of: producing a vector containing the prodigiosin biosynthetic gene cluster; transforming a cell with the vector; and culturing the transformed cell. The algicidal agent contains prodigiosin.
Abstract:
PURPOSE: A microorganism Alteromonas sp. 00SS11568 and a method for preparation of extracellular polysaccharide therefrom are provided, which polysaccharide is heteropolysaccharide consisting of glucose and galactose in a ratio of 3:1, and has improved emulsion stability, so that it can be used as biological materials for production of industrial materials. CONSTITUTION: The microorganism Alteromonas sp. 00SS11568(KCTC 10324BP) produces exopolysaccharide p-11568 which consists of glucose and galactose in a ratio of 3:1 and has molecular weight of 440 kDa, wherein Alteromonas sp. 00SS11568(KCTC 10324BP) is isolated from the biological membrane form on the sea contacting with rivers. The method for preparation of exopolysaccharide p-11568 comprises the steps of: inoculating Alteromonas sp. 00SS11568(KCTC 10324BP) in a medium containing inorganic nitrogen, organic nitrogen, inorganic phosphate, MgSO4, CaCl2 and glucose; and culturing it at 25 deg. C and pH 8.
arctica ) KOPRI 21653 및 상기 균주 유래 엑소폴리사카라이드(exopolysaccharide)에 관한 것으로, 더욱 자세하게는 슈도알터로모나스 알티카( Pseudoaltermonas
arctica ) KOPRI 21653 및 상기 균주 유래 항동결능을 가지는 신규 엑소폴리사카라이드, 그 제조 방법 및 이를 함유하는 항동결용 조성물에 관한 것이다. 본 발명에 따른 신규의 엑소폴리사카라이드 및 이를 함유하는 항동결 조성물은 조직의 손상을 최소화하면서 세포 및 조직을 포함하는 생물학적 시료를 냉장, 냉동 및 유리화 상태로 보호 또는 보존하는데 매우 유용하다.
Abstract:
PURPOSE: A Pseudoaltermonas arctica(KOPRI 21653) and exopolysaccharide derived from the same are provided to minimize tissue damage and to protect biological samples. CONSTITUTION: An exopolysaccharide having cryoprotective ability is derived from Pseudoaltermonas arctica KOPRI 21653(KCTC 11233BP). The mole ratio of glucose and galactose is 1.5:1. A method for preparing the exopolysaccharide comprises: a step of culturing Pseudoaltermonas arctica KOPRI 21653; a step of adding alcohol to the culture media and collecting precipitate; a step of removing protein from the precipitate; a step of adding alcohol and precipitating again; and a step of dialyzing the precipitate and collecting materials in the dialysis membrane.
Abstract:
A method for preparing a drug delivery carrier using exopolysaccharide produced from Hahella Chejuensis mutant m10356 is provided to obtain the drug delivery carrier which shows continuous and excellent drug releasing effect in neutral pH, thereby capable of easily delivering the drug to small intestine or large intestine. The method comprises the steps of: (a) after mixing 100 parts by weight of a vegetable oil, 10 parts by weight of exopolysaccharide, and a target drug selected from the group consisting of mesalazine, sulfasalazine, ibuprofen, prednisolone, dexamethasone, budesonide, beclomethasone, flucticasone, tioxocortal, hydrocortisone, cyclosporin, methotrexate, domperidone, 5-fluorouracil, bisacodyl, fiber, lactic acid bacteria, insulin, vasopressin, growth hormone, growth hormone stimulant, colony stimulant, calcitonin, immunoglobulin, diltiazem, verapamil, nifedipine, captopril, theophylline, naproxen and a mixture thereof, agitating it to form an emulsion, wherein the exopolysaccharide consists of glucose, galactose and galactosamine in a weight ratio of 1:1:1.1, has galacturonic acid as a supplemental sugar, and a molecular weight of 1.39x10^6Da; (b) after adding an acetic acid to the emulsion obtained from the step(a) with agitation, forming exopolysaccharide beads therefrom; and (c) centrifuging the reaction product obtained from the step(b) to recover a spherical bead shaped drug delivery carrier therefrom.
Abstract:
PURPOSE: A cold shock protein gene isolated from Streptomyces sp. AA8321 and uses thereof are provided, thereby increasing survival rate of useful microorganisms and improving low temperature tolerance of lactic acid bacteria or low temperature storage required useful microorganisms. CONSTITUTION: The cold shock protein gene csp isolated from Streptomyces sp. AA8321(KCTC 0518BP) has the nucleotide sequence set forth in SEQ ID NO:1. The cold shock protein isolated from Streptomyces sp. AA8321(KCTC 0518BP) has the amino acid sequence set forth in SEQ ID NO:2. The method for producing the cold shock protein comprises the steps of: constructing a recombinant expression vector containing the cold shock protein gene csp of SEQ ID NO:1; transforming E. coli with the recombinant expression vector containing the cold shock protein gene csp of SEQ ID NO:1 to produce E. coli LMG194(KCTC 10354BP); and culturing E. coli LMG194(KCTC 10354BP).
Abstract translation:目的:从Streptomyces sp。分离的冷休克蛋白基因。 提供了AA8321及其用途,从而提高了有用微生物的存活率,提高了乳酸菌的低温耐受性或需要有用微生物的低温贮藏。 构成:从Streptomyces sp。分离的冷休克蛋白基因csp AA8321(KCTC 0518BP)具有SEQ ID NO:1所示的核苷酸序列。 从链霉菌分离的冷休克蛋白 AA8321(KCTC 0518BP)具有SEQ ID NO:2所示的氨基酸序列。 制备冷休克蛋白的方法包括以下步骤:构建含有SEQ ID NO:1的冷休克蛋白基因csp的重组表达载体; 用含有SEQ ID NO:1的冷休克蛋白基因csp的重组表达载体转化大肠杆菌以产生大肠杆菌LMG194(KCTC 10354BP); 并培养大肠杆菌LMG194(KCTC 10354BP)。